Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
13.03
-1.92 (-12.84%)
At close: Apr 28, 2026, 4:00 PM EDT
13.27
+0.24 (1.84%)
After-hours: Apr 28, 2026, 7:54 PM EDT
Relay Therapeutics Revenue
In the year 2025, Relay Therapeutics had annual revenue of $15.36M with 53.44% growth. Relay Therapeutics had revenue of $7.00M in the quarter ending December 31, 2025.
Revenue (ttm)
$15.36M
Revenue Growth
+53.44%
P/S Ratio
160.50
Revenue / Employee
$79,974
Employees
192
Market Cap
2.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.36M | 5.35M | 53.44% |
| Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
| Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
| Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
| Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
| Dec 31, 2020 | 82.65M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 673.00M |
| ADMA Biologics | 510.17M |
| Zai Lab | 460.16M |
| Tarsus Pharmaceuticals | 451.36M |
| IDEAYA Biosciences | 218.71M |
| Soleno Therapeutics | 190.41M |
| Immunome | 6.94M |
| Celldex Therapeutics | 1.55M |
RLAY News
- 1 day ago - Relay Therapeutics Transcript: Study result - Transcripts
- 1 day ago - Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer - GlobeNewsWire
- 26 days ago - Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 - GlobeNewsWire
- 6 weeks ago - Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients? - Benzinga
- 6 weeks ago - Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 - GlobeNewsWire
- 6 weeks ago - Relay Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 2 months ago - Relay Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - GlobeNewsWire